# Akebia Therapeutics, Inc.: overview

AKBA · Nasdaq · CIK 1517022 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akba.md) · [Financials](/companies/akba/financials.md) · [Filings](/companies/akba/filings.md) · [Insiders](/companies/akba/insiders.md)

Latest reported revenue: [$49.1m](/filings/0001517022-26-000051.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001517022-26-000051).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [37.4](/filings/0001517022-25-000046.md) | [46.5 d](/filings/0001517022-26-000020.md) | [57.3](/filings/0001517022-26-000039.md) | [62.5](/filings/0001517022-26-000051.md) | [58.8](/filings/0001517022-25-000046.md) | [57.6 d](/filings/0001517022-26-000020.md) | [53.5](/filings/0001517022-26-000039.md) | [49.1](/filings/0001517022-26-000051.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(33.4%)](/filings/0001517022-25-000046.md) | [(30.8%) d](/filings/0001517022-26-000020.md) | [23.6%](/filings/0001517022-26-000039.md) | [22.6%](/filings/0001517022-26-000051.md) | [7.6%](/filings/0001517022-25-000046.md) | [(14.8%) d](/filings/0001517022-26-000020.md) | [(8.8%)](/filings/0001517022-26-000039.md) | [(12.9%)](/filings/0001517022-26-000051.md) |
| Net margin | % | [(53.5%)](/filings/0001517022-25-000046.md) | [(49.0%) d](/filings/0001517022-26-000020.md) | [10.7%](/filings/0001517022-26-000051.md) | [0.4%](/filings/0001517022-26-000051.md) | [0.9%](/filings/0001517022-25-000046.md) | [(21.2%) d](/filings/0001517022-26-000020.md) | [(16.9%)](/filings/0001517022-26-000051.md) | [(18.1%)](/filings/0001517022-26-000051.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001517022-25-000046.md) | not reported | [0.03](/filings/0001517022-26-000039.md) | [0.00](/filings/0001517022-26-000051.md) | [0.00](/filings/0001517022-25-000046.md) | not reported | [(0.03)](/filings/0001517022-26-000039.md) | [(0.03)](/filings/0001517022-26-000051.md) |
| Free cash flow | $m | [(6.7) d](/filings/0001517022-25-000046.md) | [(4.5) d](/filings/0001517022-26-000020.md) | [(13.6)](/filings/0001517022-26-000039.md) | [22.2 d](/filings/0001517022-26-000051.md) | [28.0 d](/filings/0001517022-25-000046.md) | [31.1 d](/filings/0001517022-26-000020.md) | [(21.3)](/filings/0001517022-26-000039.md) | [2.4 d](/filings/0001517022-26-000051.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [212](/filings/0001628280-23-030697.md) | [292](/filings/0001628280-24-011270.md) | [195](/filings/0001517022-26-000020.md) | [160](/filings/0001517022-26-000020.md) | [236](/filings/0001517022-26-000020.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(125.0%)](/filings/0001628280-23-030697.md) | [(27.6%)](/filings/0001628280-24-011270.md) | [(23.8%)](/filings/0001517022-26-000020.md) | [(31.5%)](/filings/0001517022-26-000020.md) | [9.9%](/filings/0001517022-26-000020.md) |
| Net margin | % | [(133.3%)](/filings/0001628280-23-030698.md) | [(32.2%)](/filings/0001628280-24-011270.md) | [(26.7%)](/filings/0001517022-26-000020.md) | [(43.3%)](/filings/0001517022-26-000020.md) | [(2.3%)](/filings/0001517022-26-000020.md) |
| Diluted EPS | $ per share | [(1.70)](/filings/0001628280-23-030697.md) | [(0.52)](/filings/0001628280-24-011270.md) | [(0.28)](/filings/0001517022-26-000020.md) | [(0.33)](/filings/0001517022-26-000020.md) | [(0.02)](/filings/0001517022-26-000020.md) |
| Free cash flow | $m | [(253)](/filings/0001628280-23-030697.md) | [(73.3)](/filings/0001628280-24-011270.md) | [(23.4)](/filings/0001517022-26-000020.md) | [(40.7)](/filings/0001517022-26-000020.md) | [67.7](/filings/0001517022-26-000020.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/akba/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $22.8m | 19,986,374 |  | Added +1,293,078 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.9m | 11,322,143 |  | Added +155,433 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $10.4m | 9,151,524 |  | Added +7,358,904 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $7.7m | 6,727,302 |  | Added +275,050 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $6.1m | 5,390,853 |  | Reduced −6,223,153 |
| [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $4.9m | 4,273,026 |  | Added +3,843,357 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $4.2m | 3,689,167 |  | Added +86,340 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $3.6m | 3,196,605 |  | Added +811,892 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.9m | 2,533,977 |  | Added +318,536 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $2.8m | 2,436,673 |  | Added +1,138,872 |

## Recent filings

[All 872 filings](/companies/akba/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 16:06 ET | [8-K](/filings/0001517022-26-000075.md) | 3.01 Delisting notice | 0001517022-26-000075 |
| 2026-10-14 | 11:57 ET | [8-K](/filings/0001517022-26-000071.md) | 5.02 Departure or appointment of officers or directors | 0001517022-26-000071 |
| 2026-08-05 | 20:10 ET | [10-Q](/filings/0001517022-26-000051.md) | Quarterly report, period 2026-06-30 | 0001517022-26-000051 |
| 2026-08-05 | 20:09 ET | [8-K](/filings/0001517022-26-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000050 |
| 2026-06-30 | 12:05 ET | [8-K](/filings/0001517022-26-000047.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-26-000047 |
| 2026-06-22 | 20:16 ET | [8-K](/filings/0001517022-26-000043.md) | 5.07 Shareholder vote results | 0001517022-26-000043 |
| 2026-05-07 | 11:24 ET | [10-Q](/filings/0001517022-26-000039.md) | Quarterly report, period 2026-03-31 | 0001517022-26-000039 |
| 2026-05-07 | 11:05 ET | [8-K](/filings/0001517022-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000038 |
| 2026-04-28 | 20:12 ET | [DEF 14A](/filings/0001517022-26-000034.md) | Proxy statement, period 2026-04-28 | 0001517022-26-000034 |
| 2026-04-01 | 20:48 ET | [8-K](/filings/0001517022-26-000024.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001517022-26-000024 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001517022-26-000020.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cf147353-c125-4eed-a26e-0e06053d1e9a)

## About the filer

- CIK: 1517022
- Tickers: AKBA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.